As we previously reported, on September 24, 2024, the District Court for the Northern District of West Virginia denied Regeneron’s motion seeking ...

Sunir Garg, MD, shares insights on new data on aflibercept 8 mg, faricimab, and the impact of social determinants of health, ...

Indian drugmaker Biocon subsidiary Biocon Biologicals has released a new extension study evaluating MYL-1701P, a proposed ...

This NMA bridges the gap between trials for both therapies and compare them to one another based on existing data.

A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

Researchers assessed the efficacy of aflibercept 8 mg vs conventional 2 mg doses at 96 weeks in patients with diabetic ...

Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.

Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) data for EYLEA HD (aflibercept) Injection 8 mg from an ...

CHICAGO, CA, UNITED STATES, October 18, 2024 /EINPresswire / -- The Global Age-Related Macular Degeneration (AMD) <a target=_blank href= ...

The most pressing challenges include the financial and emotional burdens associated with frequent, long-term treatments for ...